Trial reportTrials2026
Interim analysis in clinical trials: caution against premature conclusions-the SWOG multiple myeloma S0777 case study.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterim monitoring for efficacy and futility provides critical decision-making boundaries on early termination of randomized clinical trials. Such analyses can accelerate access to effective therapies and limit exposure to ineffective ones, but this must be weighed against premature closure that can risk obscuring a true treatment benefit. We discuss these considerations and present a case study highlighting the importance of following a well-designed interim analysis plan. METHODS AND
findingsSWOG Cancer Research Network (SWOG) S0777 was a randomized phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) versus Rd in newly diagnosed multiple myeloma that incorporated two pre-planned interim analyses. At both interim analyses, while the futility stopping boundaries were not crossed, the accumulating data suggested a limited or diminishing benefit in progression-free survival (PFS). In contrast, at final analysis, VRd demonstrated significant improvement in both PFS (hazard ratio (HR) = 0.71, p = 0.0018) and overall survival (HR = 0.71, p = 0.025) compared to Rd, helping establish VRd as standard of care. Retrospective analysis shows that use of common alternative futility stopping rules would have also not been crossed, despite the lack of positive results at the interim analysis.
conclusionsS0777's success underscores the importance of pre-specified interim monitoring plans and cautions against premature trial termination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.